Cannovum AG

  • WKN: A2LQU2
  • ISIN: DE000A2LQU21
  • Land: Deutschland

Nachricht vom 25.11.2021 | 13:20

Cannovum AG decides to enter the recreational cannabis market

DGAP-News: Cannovum AG / Key word(s): Strategic Company Decision
25.11.2021 / 13:20
The issuer is solely responsible for the content of this announcement.

The coalition agreement of the future German government presented yesterday confirmed the legalization of recreational cannabis for adult use. The management board of Cannovum AG (stock exchanges Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has thereafter decided to enter this market. The present offer in the field of medical cannabis will be maintained and further expanded.

Although details of the implementation are not yet known, Cannovum AG welcomes the intended responsible legalization as an acknowledgement of social reality. There is now an opportunity to form a responsible cannabis legalization with effective youth and consumer protection. Part of this is to learn from the pharmaceutical cannabis market in setting up the regulatory framework to offer consumers safe, high-quality cannabis and to protect them from qualities that can be hazardous to their health.

"We will do our part to provide the German market with high-quality cannabis. In doing so, we can draw on our extensive experience with medical cannabis and will also offer products of the highest quality for recreational use under our Cannovum brand," said Pia Marten, CEO of Cannovum AG.

The German medical cannabis market is already the key market in Europe due to high patient numbers and regulatory standards. Germany is therefore in a strong position to lead the way in Europe. Cannovum expects Germany to send a signal to other countries for legalization by opening the market for recreational cannabis.


Linda Rasch, IR & PR, Cannovum AG
Phone +49 30 3982 163 62,

Cannovum AG is the first German listed medical cannabis company. The shares are traded on the Düsseldorf, Munich, Berlin, Hamburg and gettex stock exchanges. Through its subsidiary Cannovum Health eG, Cannovum is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the import of high-quality cannabinoid products, medical-scientific education and all-encompassing distribution for simplified and facilitated access to cannabis-based therapies.

For more information, visit

25.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

Aktuelle Research-Studie


Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021